Accelerating Precision Medicine with Companion Diagnostics for NGS and PCR

Thermo Fisher Scientific empowers biopharma and diagnostic partners to accelerate precision medicine through trusted companion diagnostics (CDx) solutions built on next-generation sequencing (NGS), real-time PCR and digital PCR (dPCR) technologies.

 

As a global leader in molecular diagnostics, we combine deep scientific expertise, regulatory experience, and end-to-end development capabilities to enable targeted therapy selection, predictive biomarker testing, and patient stratification. Our NGS and qPCR & dPCR-based companion diagnostics platforms deliver accurate, scalable, and regulatory-ready solutions that help transform genomic insights into approved clinical applications.

Companion diagnostics solutions

Next-Generation Sequencing (NGS)

Thermo Fisher Scientific’s NGS solutions, including Ion Torrent Genexus Dx NGS systems and Oncomine Dx Express Test, enable comprehensive genomic profiling for oncology, rare diseases, and infectious disease diagnostics. Designed for reproducibility, high throughput, and scalability, these platforms deliver reliable insights that power companion diagnostics and advance precision medicine.

Real-time PCR & Digital PCR

Thermo Fisher Scientific’s QuantStudio™ Real-Time PCR Dx instruments, together with Diomni™ Enterprise Dx Software, reagents, and assays, deliver sensitive, reproducible, and scalable performance for molecular diagnostic applications. Designed to meet the rigorous demands of companion diagnostics development, these solutions provide the accuracy and reliability needed to support assays in oncology, pharmacogenomics, and infectious disease testing, while dPCR technology offers additional capabilities for ultra-sensitive quantification and absolute measurement.

Companion diagnostics frequently asked questions

We provide end-to-end CDx development support, including assay design, analytical validation, clinical trial testing, regulatory submissions, and global deployment. Our team has extensive experience collaborating with pharma partners and regulatory agencies to bring CDx-enabled therapies to market.

Platform selection depends on biomarker type, complexity, throughput, and required sensitivity. Thermo Fisher experts can help evaluate the optimal technology based on your therapeutic and diagnostic goals.

For In Vitro Diagnostic Use.

PMR-001275